These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 20150372)

  • 1. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
    Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
    Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
    Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
    Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
    Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
    Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
    Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
    Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
    van den Bent MJ; Brandes AA; Rampling R; Kouwenhoven MC; Kros JM; Carpentier AF; Clement PM; Frenay M; Campone M; Baurain JF; Armand JP; Taphoorn MJ; Tosoni A; Kletzl H; Klughammer B; Lacombe D; Gorlia T
    J Clin Oncol; 2009 Mar; 27(8):1268-74. PubMed ID: 19204207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
    Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
    Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
    Yung WK; Vredenburgh JJ; Cloughesy TF; Nghiemphu P; Klencke B; Gilbert MR; Reardon DA; Prados MD
    Neuro Oncol; 2010 Oct; 12(10):1061-70. PubMed ID: 20615922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
    de Groot JF; Gilbert MR; Aldape K; Hess KR; Hanna TA; Ictech S; Groves MD; Conrad C; Colman H; Puduvalli VK; Levin V; Yung WK
    J Neurooncol; 2008 Oct; 90(1):89-97. PubMed ID: 18581057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
    Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
    J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
    J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
    J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Friedman AH; Herndon JE; Marcello J; Norfleet JA; McLendon RE; Sampson JH; Friedman HS
    J Neurooncol; 2010 Jan; 96(2):219-30. PubMed ID: 19562254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
    Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
    Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK
    Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
    Krishnan S; Brown PD; Ballman KV; Fiveash JB; Uhm JH; Giannini C; Jaeckle KA; Geoffroy FJ; Nabors LB; Buckner JC;
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1192-9. PubMed ID: 16626884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
    Chamberlain MC; Grimm S; Phuphanich S; Recht L; Zhu JZ; Kim L; Rosenfeld S; Fadul CE;
    J Neurooncol; 2014 Jun; 118(2):335-343. PubMed ID: 24740196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.